Project Grant 057905053

The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...

Simmbion LLC was awarded a $255,136 Project Grant from the National Science Foundation's Small Business Technology Transfer program to develop a system for manufacturing drug therapies inside the human body. Over the one-year period from April 2022 to March 2023, the company will genetically engineer symbiotic blood organisms to express and secrete two therapeutic proteins - β-glucocerebrosidase to treat Gaucher's disease and insulin for diabetes treatment. In vitro and in vivo testing will...

Grant Award Summary Molecular Intelligence LLC received a $435,882 Small Business Innovation Research (SBIR) Phase I project grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, with completion targeted for February 28, 2027. The award funds development of advanced artificial intelligence-powered software tools designed to model receptor-ligand interactions from cryo-electron...

Federal Grant Award Summary Electronic Biosciences, Inc. (EBS) received a $350,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) on June 5, 2025, with an ultimate completion date of May 31, 2027. During this Phase I SBIR award, EBS is developing and optimizing a novel enzyme-based, single-molecule protein sequencing system designed to overcome the limitations of current proteomic tools...

Biosapien Inc. received a $256,000 Project Grant award from the National Science Foundation on May 1, 2021 to develop a novel 3D printed biodegradable mesh delivering active pharmaceutical ingredients in a sustained and localized manner under the Small Business Innovation Research Phase I program. The SBIR Phase I grant supports the proof-of-concept stage of developing Biosapien's technology, with the work expected to be completed by June 30, 2022. The NSF Technology, Innovation, and...

Biomesense Inc. received a $883,212 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences to develop a novel biosensor to accelerate investigations of the gut microbiome. The grant will support validating the microbial lysis and DNA isolation functions of a prototype biosensor over a 6-month period ending December 31, 2021. The biosensor is intended to enable dense, time-longitudinal sampling of participants' gut microbiomes in their...

Z Biotech, LLC received a $306,782 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025 through August 31, 2026. The award supports Phase I development and validation of sialoglycan-recognizing probes (SGRPs), which are engineered molecular tools derived from naturally evolved microbial molecules such as bacterial adhesins, toxin subunits, and viral hemagglutinin-esterases....

Federal Grant Award Summary Electronic Biosciences, Inc. received a Phase I Small Business Innovation Research (SBIR) Project Grant of $383,482 from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), awarded June 6, 2025, with completion targeted for May 31, 2027. The award supports development of SPINSEQ, an innovative RNA sequencing platform designed to deliver high-precision transcriptomic analysis while preserving RNA modifications...

Federal Grant Award Summary Intero Biosystems Inc. received a $349,952 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 20, 2025, with a completion date of June 19, 2026. In collaboration with the University of Michigan, the awardee is developing and validating a novel stem cell-derived human intestinal organoid (HIO) screening platform designed to improve preclinical drug testing and reduce the current 90% failure rate of drug...

Molecular Instruments, Inc. received a $306,788 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period September 30, 2025 through September 29, 2026. The award supports the development and advancement of probe technology for ultrasensitive RNA imaging utilizing Hybridization Chain Reaction (HCR) methodology. The company is developing enhanced in situ amplification-based imaging...